Clinical trial · Interventional
MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
Phase I Dose Escalation Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
NCT00207103CI-TRIAL-00001764completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in patients with advanced or metastatic solid tumors.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasm Metastasis | — | UNRESOLVED | — |
| Tumors | Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Brivanab | Drug | — | UNRESOLVED |
| Brivanib | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (6)
- type
- EXPERIMENTAL
- label
- 1
- interventionNames
- Drug: Brivanib
- type
- EXPERIMENTAL
- label
- 2
- interventionNames
- Drug: Brivanib
- type
- EXPERIMENTAL
- label
- 3
- interventionNames
- Drug: Brivanib
- type
- EXPERIMENTAL
- label
- 4
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of progressive advanced or metastatic (tumor that has spread) solid tumors * No tumor spread to the brain * Feeling well other than cancer diagnosis (i.e. lab work, no infection, etc.) * Available tumor tissue sample from prior surgery * 4-6 weeks since prior therapy and recovered from prior therapy * Men and women, ages 18 and above * Women must not be pregnant or breastfeeding * Diagnosis of advanced or metastatic (tumor that has spread) colorectal, hepatocellular (liver) or renal (kidney) cancer * Measurable disease on scans (at least one)
References
Publications (0)
Data not yet available
No reference posted for this study.